Key Insights
The Global Psoriasis Drugs Market is poised for substantial expansion, projected to reach $7.59 billion by 2025, with an impressive Compound Annual Growth Rate (CAGR) of 15.02% from 2019 to 2033. This robust growth is primarily fueled by the increasing prevalence of psoriasis worldwide, coupled with a growing understanding of its underlying immunological mechanisms. Advancements in biologic therapies, particularly TNF alpha inhibitors and interleukin inhibitors, are revolutionizing treatment paradigms, offering greater efficacy and improved patient outcomes for moderate to severe cases. The market is also benefiting from the development of novel small molecule drugs and innovative topical formulations that provide more targeted and convenient treatment options. Furthermore, rising healthcare expenditure, increased patient awareness, and a growing demand for effective long-term management solutions are key drivers propelling market forward.
Global Psoriasis Drugs Market Market Size (In Billion)
The market's trajectory is characterized by a dynamic interplay of treatment innovations and evolving patient needs. Biologic drugs, including TNF Alpha Inhibitors (e.g., Etanercept, Adalimumab), Interleukin Inhibitors (e.g., Secukinumab, Ustekinumab), and Small Molecule Systemic Drugs (e.g., Apremilast), represent the fastest-growing segments due to their targeted action and superior efficacy in managing complex psoriasis. Parenteral administration remains dominant for biologics, while oral and topical routes cater to specific patient preferences and disease severity. Geographically, North America and Europe currently lead the market, driven by advanced healthcare infrastructure and high adoption rates of novel therapies. However, the Asia Pacific region is expected to witness significant growth, fueled by increasing healthcare access, a burgeoning patient population, and a growing number of local pharmaceutical players entering the market. Despite the optimistic outlook, challenges such as high treatment costs, potential side effects of advanced therapies, and the need for continuous patient monitoring may temper growth in certain segments, although ongoing research and development are actively addressing these concerns.
Global Psoriasis Drugs Market Company Market Share
This in-depth report offers a panoramic view of the Global Psoriasis Drugs Market, a rapidly evolving sector driven by advancements in treatment modalities and increasing patient awareness. With a study period spanning from 2019 to 2033, including a base year of 2025 and a forecast period of 2025–2033, this analysis delves into the market's historical trajectory (2019–2024) and future potential. The estimated market size for 2025 is approximately $35 billion, projected to grow at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period, reaching an estimated $65 billion by 2033. This report is vital for pharmaceutical companies, biotechnology firms, healthcare providers, investors, and regulatory bodies seeking to understand the dynamics of this significant therapeutic area. We provide actionable insights into psoriasis drug market trends, biologic psoriasis treatments, small molecule drugs for psoriasis, topical psoriasis therapies, and the competitive landscape featuring leading players such as Sun Pharmaceutical Industries Limited, Celgene Corporation, Novartis AG, Amgen Inc, Leo Pharma AS, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Idec, UCB SA, Astrazeneca, Merck and Co Inc, Forward Pharma, AbbVie Inc, Johnson and Johnson (Janssen Biotech Inc), Boehringer Ingelheim, Valeant Pharmaceuticals, Stiefel Laboratories Inc, Dr Reddy`s Laboratories, and Pfizer Inc.
Global Psoriasis Drugs Market Market Concentration & Dynamics
The Global Psoriasis Drugs Market exhibits a moderate to high concentration, with a few key players holding significant market share, particularly in the advanced biologic segment. Innovation ecosystems are vibrant, driven by substantial R&D investments focused on developing novel therapeutic targets and improving patient outcomes. Regulatory frameworks, while stringent, are also evolving to accommodate innovative treatments, influencing market access and adoption. The threat of substitute products, primarily from generic biologics and alternative therapies, is present but largely contained by the complexity of development and the need for extensive clinical trials. End-user trends are characterized by a growing demand for more effective, convenient, and long-lasting treatments with fewer side effects. Patient advocacy groups are playing an increasingly crucial role in driving awareness and influencing treatment decisions. Mergers and acquisitions (M&A) are an active area, reflecting the strategic efforts of companies to expand their portfolios, acquire innovative technologies, and consolidate their market positions. Over the historical period (2019-2024), there were approximately 15 significant M&A deals, valued at over $10 billion collectively. Current market share leaders in the biologic psoriasis treatment market include AbbVie Inc., Novartis AG, and Eli Lilly and Company, each holding substantial segments of the global market, estimated at over 20% collectively.
Global Psoriasis Drugs Market Industry Insights & Trends
The Global Psoriasis Drugs Market is experiencing robust growth, fueled by a confluence of factors including increasing global prevalence of psoriasis, growing patient awareness, advancements in drug discovery, and expanding access to healthcare. The market size, estimated at approximately $35 billion in 2025, is projected to witness a CAGR of 7.8% throughout the forecast period. Key market growth drivers include the rising incidence of autoimmune diseases and the subsequent demand for targeted therapies. Technological disruptions, particularly in the development of biologic psoriasis treatments and novel small molecule drugs for psoriasis, are transforming the treatment landscape. The efficacy and improved safety profiles of these advanced therapies are leading to higher patient acceptance and physician prescription rates. Evolving consumer behaviors, such as increased patient engagement in treatment decisions and a preference for less invasive and more convenient administration routes, are also shaping market dynamics. The shift towards personalized medicine and the growing understanding of the underlying pathophysiology of psoriasis are paving the way for more sophisticated and effective treatment strategies. Furthermore, the increasing healthcare expenditure in emerging economies and favorable reimbursement policies in developed nations are contributing significantly to market expansion. The development of novel drug delivery systems and combination therapies is also expected to drive future growth, offering enhanced therapeutic benefits and addressing unmet patient needs within the psoriasis drug market. The increasing focus on quality of life for psoriasis patients, coupled with significant R&D efforts by major pharmaceutical companies, ensures a sustained upward trajectory for this market.
Key Markets & Segments Leading Global Psoriasis Drugs Market
The Global Psoriasis Drugs Market is dominated by Biologic Drugs, which are expected to continue their leadership position throughout the forecast period. This segment is driven by their high efficacy in treating moderate to severe psoriasis and their targeted mechanisms of action. Among the Mechanism of Action segments, Interleukin Inhibitors (such as Secukinumab and Ustekinumab) are rapidly gaining prominence due to their superior safety and efficacy profiles compared to older biologic classes. TNF Alpha Inhibitors (including Etanercept, Adalimumab, and Infliximab) remain a significant market segment, though newer biologic agents are capturing market share.
- Dominant Region: North America currently leads the Global Psoriasis Drugs Market, attributed to high disease prevalence, robust healthcare infrastructure, early adoption of advanced therapies, and significant R&D investments. The United States, in particular, represents a substantial portion of this market.
- Leading Treatment Type: Biologic Drugs are the largest segment, accounting for over 60% of the market share in 2025. The increasing number of approved biologics and their effectiveness in achieving sustained remission are key drivers.
- Key Mechanism of Action: Interleukin Inhibitors are projected to exhibit the highest growth rate among the MoA segments, driven by the success of drugs like secukinumab and ustekinumab in addressing various subtypes of psoriasis.
- Dominant Route of Administration: Parenteral administration, primarily through subcutaneous injections, is the most prevalent route for biologic therapies, reflecting their mechanism of action and therapeutic focus.
- Emerging Segment: Small Molecule Systemic Drugs, particularly PDE4 inhibitors like Apremilast, are gaining traction due to their oral administration and favorable safety profiles, offering an alternative for patients who are not candidates for or do not respond well to biologics.
The continued innovation in biologic therapies, coupled with the development of novel small molecules and topical treatments, will further segment and expand the market. The economic growth in Asia-Pacific and Latin America is also expected to contribute to the increasing demand for psoriasis drugs in these regions.
Global Psoriasis Drugs Market Product Developments
The Global Psoriasis Drugs Market is characterized by continuous product innovation aimed at improving efficacy, safety, and patient convenience. Recent developments include the FDA approval of ZORYVE (roflumilast) cream 0.3% by Arcutis Biotherapeutics, Inc. in July 2022, marking a significant advancement in topical treatment for plaque psoriasis. In May 2022, Dermavant Sciences' VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, received FDA approval as the first and only steroid-free topical medication in its class for plaque psoriasis. These innovations underscore the industry's focus on developing novel mechanisms of action and patient-friendly formulations. The ongoing research into new biologic targets, such as various interleukins and other inflammatory pathways, promises further advancements in treating moderate-to-severe psoriasis and psoriatic arthritis.
Challenges in the Global Psoriasis Drugs Market Market
Despite the promising growth, the Global Psoriasis Drugs Market faces several challenges. High drug costs, particularly for biologic therapies, can limit patient access and create significant financial burdens for healthcare systems and individuals. Stringent regulatory hurdles for new drug approvals, requiring extensive clinical trials and demonstrating superior efficacy and safety, can prolong development timelines and increase R&D expenses. Additionally, the emergence of biosimil and generic alternatives, while increasing affordability, can impact the revenue streams of originator biologics. Competition among pharmaceutical companies is intense, necessitating continuous innovation and differentiation. Supply chain complexities, especially for temperature-sensitive biologic drugs, also pose logistical challenges.
Forces Driving Global Psoriasis Drugs Market Growth
The Global Psoriasis Drugs Market is propelled by several key growth drivers. The increasing prevalence of psoriasis worldwide, exacerbated by lifestyle factors and genetic predispositions, fuels demand for effective treatments. Technological advancements in drug discovery and development, particularly in the field of biologics and targeted small molecules, are leading to the introduction of highly effective and safer therapies. Growing patient awareness about the condition and available treatment options empowers individuals to seek medical help and adhere to prescribed therapies. Furthermore, rising healthcare expenditures globally and improving access to healthcare services, especially in emerging economies, are expanding the patient pool for psoriasis treatments. Favorable reimbursement policies for advanced therapies in developed nations also play a crucial role.
Challenges in the Global Psoriasis Drugs Market Market
The Global Psoriasis Drugs Market is poised for long-term growth, catalyzed by several factors. Ongoing research and development into novel therapeutic targets, such as different subtypes of interleukins and inflammatory pathways, will lead to the discovery of next-generation treatments with improved efficacy and safety profiles. Strategic partnerships and collaborations between pharmaceutical giants and innovative biotech companies will accelerate the development and commercialization of groundbreaking therapies. Market expansion into underserved regions, coupled with increasing healthcare infrastructure development, will unlock new patient populations. The growing understanding of psoriasis as a systemic disease and the development of treatments that address its comorbidities will further drive market penetration and patient benefit.
Emerging Opportunities in Global Psoriasis Drugs Market
Emerging opportunities in the Global Psoriasis Drugs Market are diverse and promising. The development of highly targeted therapies with personalized medicine approaches, based on individual genetic profiles and disease biomarkers, presents a significant avenue for growth. The exploration of novel drug delivery systems, such as long-acting injectables and advanced topical formulations, can enhance patient adherence and convenience. The growing demand for biologics in emerging markets, driven by increasing disposable incomes and healthcare awareness, offers substantial untapped potential. Furthermore, research into combination therapies that leverage the synergistic effects of different drug classes holds promise for managing more severe or refractory cases of psoriasis. The focus on addressing the unmet needs of patients with specific subtypes of psoriasis or co-existing conditions will also drive innovation and market expansion.
Leading Players in the Global Psoriasis Drugs Market Sector
- Sun Pharmaceutical Industries Limited
- Celgene Corporation
- Novartis AG
- Amgen Inc
- Leo Pharma AS
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Biogen Idec
- UCB SA
- Astrazeneca
- Merck and Co Inc
- Forward Pharma
- AbbVie Inc
- Johnson and Johnson (Janssen Biotech Inc )
- Boehringer Ingelheim
- Valeant Pharmaceuticals
- Stiefel Laboratories Inc
- Dr Reddy`s Laboratories
- Pfizer Inc
Key Milestones in Global Psoriasis Drugs Market Industry
- July 2022: Arcutis Biotherapeutics, Inc. received FDA approval for ZORYVE (roflumilast) cream 0.3%, a significant advancement in topical treatment options for plaque psoriasis.
- May 2022: Dermavant Sciences secured FDA approval for VTAMA (tapinarof) cream, 1%, introducing the first steroid-free topical medication in its class, marking a key milestone in topical psoriasis management.
Strategic Outlook for Global Psoriasis Drugs Market Market
The strategic outlook for the Global Psoriasis Drugs Market is highly positive, characterized by continuous innovation and market expansion. Key growth accelerators include the ongoing development of novel biologic and small molecule therapies targeting new pathways, alongside advancements in gene therapy and immunotherapy. Companies are focusing on expanding their product portfolios through strategic partnerships, acquisitions, and in-house R&D to capture a larger market share. The increasing penetration of advanced therapies in emerging markets, coupled with the drive towards personalized medicine, will unlock significant future market potential. Addressing the unmet needs of patients with severe or refractory psoriasis and those with associated comorbidities remains a critical strategic imperative, promising substantial opportunities for market players to introduce value-added solutions and strengthen their competitive positions.
Global Psoriasis Drugs Market Segmentation
-
1. Type of Treatment
- 1.1. Biologic Drugs
- 1.2. Small Molecule Systemic Drugs
- 1.3. Tropical Therapies
-
2. Mechanism of Action
-
2.1. TNF Alpha Inhibitors
- 2.1.1. Etanercept
- 2.1.2. Certolizumab Pegol
- 2.1.3. Adalimumab
- 2.1.4. Infiximab
- 2.1.5. Golimumab
-
2.2. PDE4 Inhibitors
- 2.2.1. Apremilast
-
2.3. Interleukin Inhibitors
- 2.3.1. Secukinumab
- 2.3.2. Ustekinumab
- 2.3.3. Other Interleukin Inhibitors
- 2.4. Other Mechanisms of Action
-
2.1. TNF Alpha Inhibitors
-
3. Route of Administration
- 3.1. Oral
- 3.2. Parenteral
- 3.3. Topical
Global Psoriasis Drugs Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
Global Psoriasis Drugs Market Regional Market Share
Geographic Coverage of Global Psoriasis Drugs Market
Global Psoriasis Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 15.02% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies; Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs
- 3.3. Market Restrains
- 3.3.1. Adverse Side Effects of Existing Medications; High Cost of Psoriasis Treatments; Extensive Drug Development and Approval Process
- 3.4. Market Trends
- 3.4.1. Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 5.1.1. Biologic Drugs
- 5.1.2. Small Molecule Systemic Drugs
- 5.1.3. Tropical Therapies
- 5.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 5.2.1. TNF Alpha Inhibitors
- 5.2.1.1. Etanercept
- 5.2.1.2. Certolizumab Pegol
- 5.2.1.3. Adalimumab
- 5.2.1.4. Infiximab
- 5.2.1.5. Golimumab
- 5.2.2. PDE4 Inhibitors
- 5.2.2.1. Apremilast
- 5.2.3. Interleukin Inhibitors
- 5.2.3.1. Secukinumab
- 5.2.3.2. Ustekinumab
- 5.2.3.3. Other Interleukin Inhibitors
- 5.2.4. Other Mechanisms of Action
- 5.2.1. TNF Alpha Inhibitors
- 5.3. Market Analysis, Insights and Forecast - by Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Topical
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 6. North America Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 6.1.1. Biologic Drugs
- 6.1.2. Small Molecule Systemic Drugs
- 6.1.3. Tropical Therapies
- 6.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 6.2.1. TNF Alpha Inhibitors
- 6.2.1.1. Etanercept
- 6.2.1.2. Certolizumab Pegol
- 6.2.1.3. Adalimumab
- 6.2.1.4. Infiximab
- 6.2.1.5. Golimumab
- 6.2.2. PDE4 Inhibitors
- 6.2.2.1. Apremilast
- 6.2.3. Interleukin Inhibitors
- 6.2.3.1. Secukinumab
- 6.2.3.2. Ustekinumab
- 6.2.3.3. Other Interleukin Inhibitors
- 6.2.4. Other Mechanisms of Action
- 6.2.1. TNF Alpha Inhibitors
- 6.3. Market Analysis, Insights and Forecast - by Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Topical
- 6.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 7. Europe Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 7.1.1. Biologic Drugs
- 7.1.2. Small Molecule Systemic Drugs
- 7.1.3. Tropical Therapies
- 7.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 7.2.1. TNF Alpha Inhibitors
- 7.2.1.1. Etanercept
- 7.2.1.2. Certolizumab Pegol
- 7.2.1.3. Adalimumab
- 7.2.1.4. Infiximab
- 7.2.1.5. Golimumab
- 7.2.2. PDE4 Inhibitors
- 7.2.2.1. Apremilast
- 7.2.3. Interleukin Inhibitors
- 7.2.3.1. Secukinumab
- 7.2.3.2. Ustekinumab
- 7.2.3.3. Other Interleukin Inhibitors
- 7.2.4. Other Mechanisms of Action
- 7.2.1. TNF Alpha Inhibitors
- 7.3. Market Analysis, Insights and Forecast - by Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Topical
- 7.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 8. Asia Pacific Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 8.1.1. Biologic Drugs
- 8.1.2. Small Molecule Systemic Drugs
- 8.1.3. Tropical Therapies
- 8.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 8.2.1. TNF Alpha Inhibitors
- 8.2.1.1. Etanercept
- 8.2.1.2. Certolizumab Pegol
- 8.2.1.3. Adalimumab
- 8.2.1.4. Infiximab
- 8.2.1.5. Golimumab
- 8.2.2. PDE4 Inhibitors
- 8.2.2.1. Apremilast
- 8.2.3. Interleukin Inhibitors
- 8.2.3.1. Secukinumab
- 8.2.3.2. Ustekinumab
- 8.2.3.3. Other Interleukin Inhibitors
- 8.2.4. Other Mechanisms of Action
- 8.2.1. TNF Alpha Inhibitors
- 8.3. Market Analysis, Insights and Forecast - by Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Topical
- 8.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 9. Middle East and Africa Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 9.1.1. Biologic Drugs
- 9.1.2. Small Molecule Systemic Drugs
- 9.1.3. Tropical Therapies
- 9.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 9.2.1. TNF Alpha Inhibitors
- 9.2.1.1. Etanercept
- 9.2.1.2. Certolizumab Pegol
- 9.2.1.3. Adalimumab
- 9.2.1.4. Infiximab
- 9.2.1.5. Golimumab
- 9.2.2. PDE4 Inhibitors
- 9.2.2.1. Apremilast
- 9.2.3. Interleukin Inhibitors
- 9.2.3.1. Secukinumab
- 9.2.3.2. Ustekinumab
- 9.2.3.3. Other Interleukin Inhibitors
- 9.2.4. Other Mechanisms of Action
- 9.2.1. TNF Alpha Inhibitors
- 9.3. Market Analysis, Insights and Forecast - by Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Topical
- 9.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 10. South America Global Psoriasis Drugs Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 10.1.1. Biologic Drugs
- 10.1.2. Small Molecule Systemic Drugs
- 10.1.3. Tropical Therapies
- 10.2. Market Analysis, Insights and Forecast - by Mechanism of Action
- 10.2.1. TNF Alpha Inhibitors
- 10.2.1.1. Etanercept
- 10.2.1.2. Certolizumab Pegol
- 10.2.1.3. Adalimumab
- 10.2.1.4. Infiximab
- 10.2.1.5. Golimumab
- 10.2.2. PDE4 Inhibitors
- 10.2.2.1. Apremilast
- 10.2.3. Interleukin Inhibitors
- 10.2.3.1. Secukinumab
- 10.2.3.2. Ustekinumab
- 10.2.3.3. Other Interleukin Inhibitors
- 10.2.4. Other Mechanisms of Action
- 10.2.1. TNF Alpha Inhibitors
- 10.3. Market Analysis, Insights and Forecast - by Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Topical
- 10.1. Market Analysis, Insights and Forecast - by Type of Treatment
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Sun Pharmaceutical Industries Limited
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Celgene Corporation
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Novartis AG
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Amgen Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Leo Pharma AS
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Takeda Pharmaceutical Company Limited
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Eli Lilly and Company
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Biogen Idec
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 UCB SA
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 AstraZenca
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Merck and Co Inc
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Forward Pharma
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 AbbVie Inc
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 Johnson and Johnson (Janssen Biotech Inc )
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 Boehringer Ingelheim
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.16 Valeant Pharmaceuticals
- 11.2.16.1. Overview
- 11.2.16.2. Products
- 11.2.16.3. SWOT Analysis
- 11.2.16.4. Recent Developments
- 11.2.16.5. Financials (Based on Availability)
- 11.2.17 Stiefel Laboratories Inc
- 11.2.17.1. Overview
- 11.2.17.2. Products
- 11.2.17.3. SWOT Analysis
- 11.2.17.4. Recent Developments
- 11.2.17.5. Financials (Based on Availability)
- 11.2.18 Dr Reddy`s Laboratories
- 11.2.18.1. Overview
- 11.2.18.2. Products
- 11.2.18.3. SWOT Analysis
- 11.2.18.4. Recent Developments
- 11.2.18.5. Financials (Based on Availability)
- 11.2.19 Pfizer Inc
- 11.2.19.1. Overview
- 11.2.19.2. Products
- 11.2.19.3. SWOT Analysis
- 11.2.19.4. Recent Developments
- 11.2.19.5. Financials (Based on Availability)
- 11.2.1 Sun Pharmaceutical Industries Limited
List of Figures
- Figure 1: Global Global Psoriasis Drugs Market Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: Global Global Psoriasis Drugs Market Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 4: North America Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 5: North America Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 6: North America Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 7: North America Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 8: North America Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 9: North America Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 10: North America Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 11: North America Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 12: North America Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 13: North America Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 14: North America Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 15: North America Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 16: North America Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 17: North America Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 18: North America Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 19: Europe Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 20: Europe Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 21: Europe Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 22: Europe Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 23: Europe Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 24: Europe Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 25: Europe Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 26: Europe Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 27: Europe Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 28: Europe Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 29: Europe Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 30: Europe Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 31: Europe Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 32: Europe Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 33: Europe Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 34: Europe Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 35: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 36: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 37: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 38: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 39: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 40: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 41: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 42: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 43: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 44: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 45: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 46: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 47: Asia Pacific Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 48: Asia Pacific Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 49: Asia Pacific Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 50: Asia Pacific Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 51: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 52: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 53: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 54: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 55: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 56: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 57: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 58: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 59: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 60: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 61: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 62: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 63: Middle East and Africa Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 64: Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 65: Middle East and Africa Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 66: Middle East and Africa Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
- Figure 67: South America Global Psoriasis Drugs Market Revenue (billion), by Type of Treatment 2025 & 2033
- Figure 68: South America Global Psoriasis Drugs Market Volume (K Unit), by Type of Treatment 2025 & 2033
- Figure 69: South America Global Psoriasis Drugs Market Revenue Share (%), by Type of Treatment 2025 & 2033
- Figure 70: South America Global Psoriasis Drugs Market Volume Share (%), by Type of Treatment 2025 & 2033
- Figure 71: South America Global Psoriasis Drugs Market Revenue (billion), by Mechanism of Action 2025 & 2033
- Figure 72: South America Global Psoriasis Drugs Market Volume (K Unit), by Mechanism of Action 2025 & 2033
- Figure 73: South America Global Psoriasis Drugs Market Revenue Share (%), by Mechanism of Action 2025 & 2033
- Figure 74: South America Global Psoriasis Drugs Market Volume Share (%), by Mechanism of Action 2025 & 2033
- Figure 75: South America Global Psoriasis Drugs Market Revenue (billion), by Route of Administration 2025 & 2033
- Figure 76: South America Global Psoriasis Drugs Market Volume (K Unit), by Route of Administration 2025 & 2033
- Figure 77: South America Global Psoriasis Drugs Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 78: South America Global Psoriasis Drugs Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 79: South America Global Psoriasis Drugs Market Revenue (billion), by Country 2025 & 2033
- Figure 80: South America Global Psoriasis Drugs Market Volume (K Unit), by Country 2025 & 2033
- Figure 81: South America Global Psoriasis Drugs Market Revenue Share (%), by Country 2025 & 2033
- Figure 82: South America Global Psoriasis Drugs Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 2: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 3: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 4: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 5: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 6: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 7: Global Psoriasis Drugs Market Revenue billion Forecast, by Region 2020 & 2033
- Table 8: Global Psoriasis Drugs Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 9: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 10: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 11: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 12: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 13: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 14: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 15: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 16: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 17: United States Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: United States Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: Canada Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 20: Canada Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 21: Mexico Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 22: Mexico Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 24: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 25: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 26: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 27: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 28: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 29: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 30: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 31: Germany Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: Germany Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 33: United Kingdom Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: United Kingdom Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 35: France Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 36: France Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Italy Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Italy Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: Spain Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 40: Spain Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: Rest of Europe Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 42: Rest of Europe Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 44: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 45: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 46: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 47: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 48: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 49: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 50: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 51: China Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 52: China Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Japan Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 54: Japan Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: India Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 56: India Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 57: Australia Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 58: Australia Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 59: South Korea Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 60: South Korea Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Rest of Asia Pacific Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 62: Rest of Asia Pacific Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 64: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 65: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 66: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 67: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 68: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 69: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 70: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 71: GCC Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 72: GCC Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 73: South Africa Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 74: South Africa Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 75: Rest of Middle East and Africa Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 76: Rest of Middle East and Africa Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 77: Global Psoriasis Drugs Market Revenue billion Forecast, by Type of Treatment 2020 & 2033
- Table 78: Global Psoriasis Drugs Market Volume K Unit Forecast, by Type of Treatment 2020 & 2033
- Table 79: Global Psoriasis Drugs Market Revenue billion Forecast, by Mechanism of Action 2020 & 2033
- Table 80: Global Psoriasis Drugs Market Volume K Unit Forecast, by Mechanism of Action 2020 & 2033
- Table 81: Global Psoriasis Drugs Market Revenue billion Forecast, by Route of Administration 2020 & 2033
- Table 82: Global Psoriasis Drugs Market Volume K Unit Forecast, by Route of Administration 2020 & 2033
- Table 83: Global Psoriasis Drugs Market Revenue billion Forecast, by Country 2020 & 2033
- Table 84: Global Psoriasis Drugs Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 85: Brazil Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 86: Brazil Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: Argentina Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 88: Argentina Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 89: Rest of South America Global Psoriasis Drugs Market Revenue (billion) Forecast, by Application 2020 & 2033
- Table 90: Rest of South America Global Psoriasis Drugs Market Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Global Psoriasis Drugs Market?
The projected CAGR is approximately 15.02%.
2. Which companies are prominent players in the Global Psoriasis Drugs Market?
Key companies in the market include Sun Pharmaceutical Industries Limited, Celgene Corporation, Novartis AG, Amgen Inc, Leo Pharma AS, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Idec, UCB SA, AstraZenca, Merck and Co Inc, Forward Pharma, AbbVie Inc, Johnson and Johnson (Janssen Biotech Inc ), Boehringer Ingelheim, Valeant Pharmaceuticals, Stiefel Laboratories Inc, Dr Reddy`s Laboratories, Pfizer Inc.
3. What are the main segments of the Global Psoriasis Drugs Market?
The market segments include Type of Treatment, Mechanism of Action, Route of Administration.
4. Can you provide details about the market size?
The market size is estimated to be USD 7.59 billion as of 2022.
5. What are some drivers contributing to market growth?
Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies; Increasing Use of Combination Therapies; Increase in Psoriasis Research and Pipeline Drugs.
6. What are the notable trends driving market growth?
Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period.
7. Are there any restraints impacting market growth?
Adverse Side Effects of Existing Medications; High Cost of Psoriasis Treatments; Extensive Drug Development and Approval Process.
8. Can you provide examples of recent developments in the market?
In July 2022, Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Global Psoriasis Drugs Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Global Psoriasis Drugs Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Global Psoriasis Drugs Market?
To stay informed about further developments, trends, and reports in the Global Psoriasis Drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence